Combination therapy for the treatment of ocular neovascularization.
about
Microvascular complications and diabetic retinopathy: recent advances and future implicationsToday and future of age-related macular degenerationInhibition of oxygen-induced ischemic retinal neovascularization with adenoviral 15-lipoxygenase-1 gene transfer via up-regulation of PPAR-γ and down-regulation of VEGFR-2 expressionADAM9 is involved in pathological retinal neovascularizationCost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization.Nucleic acid aptamers: clinical applications and promising new horizonsPLD1-dependent PKCgamma activation downstream to Src is essential for the development of pathologic retinal neovascularization.Triamcinolone acetonide as an adjunct to bevacizumab for prevention of corneal neovascularization in a rat modelCharacterization of oxygen-induced retinopathy in mice carrying an inactivating point mutation in the catalytic site of ADAM15.Analysis of candidate genes for macular telangiectasia type 2Notch signaling in ocular vasculature development and diseases.Retinal Inhibition of CCR3 Induces Retinal Cell Death in a Murine Model of Choroidal NeovascularizationTMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model.Adenoviral 15-lipoxygenase-1 gene transfer inhibits hypoxia-induced proliferation of retinal microvascular endothelial cells in vitroOverexpression of 15-lipoxygenase-1 in oxygen-induced ischemic retinopathy inhibits retinal neovascularization via downregulation of vascular endothelial growth factor-A expression.Intravitreal injection of TIMP3 or the EGFR inhibitor erlotinib offers protection from oxygen-induced retinopathy in mice.Degradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retina.Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stressA Role for PPARbeta/delta in Ocular AngiogenesisPredictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.Genetic predictors of response to photodynamictherapy.Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes.ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice.AAV-CRISPR/Cas9-Mediated Depletion of VEGFR2 Blocks Angiogenesis In Vitro.Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia.An apelin receptor antagonist prevents pathological retinal angiogenesis with ischemic retinopathy in mice.Single-session photodynamic therapy combined with intravitreal ranibizumab for neovascular age-related macular degeneration: a comprehensive functional retinal assessment.Expression profile and regulation of telomerase reverse transcriptase on oxygen-induced retinal neovascularization.The effects of topical everolimus and sunitinib on corneal neovascularization.The important role of ADAM8 in the progression of hepatocellular carcinoma induced by diethylnitrosamine in mice.
P2860
Q26822476-70D912D1-87EC-4418-AAF5-DB99BFCE0170Q26865643-9A2CF34E-000B-4A87-B2AF-CF957E5232A0Q27332433-C0F9F00D-0335-4465-8C37-241556C1A28AQ28591506-12B8D289-048D-4D16-B75B-A6000CC2C370Q33353392-1829AD62-69B4-4A46-8D2F-8C8BFF45A651Q33694084-1F3597C4-4A33-4E28-8B9D-11A18B5A8A22Q34028112-FB2AA9D7-4EFF-490A-9E2B-64932B2676AEQ34122706-B743C518-8FF4-4BDD-A006-784808073491Q34272294-3AE41C45-3AC4-4C04-A56A-DDE939F088FDQ34406075-EE9C4EB2-62D7-4816-9159-D88FF8DCB4E4Q34410734-CD6BB9B2-3D7F-4228-B3BD-38BCC2FE7D9EQ35719022-B4344B81-6FFE-4972-9D6C-AE026B49C040Q36053934-C8BD46C7-C39A-4B8A-BBA3-C55D11164DBAQ36232684-462904A8-3A0F-460D-A652-44552A6FE2BDQ36358667-3213860A-7D7F-410E-A672-9DD6FF1E83D6Q36458943-A24FAC99-9A28-4DAB-9D14-F2E380DE705FQ36581303-85032EB6-21B7-47C3-852C-C25AF33792F0Q37095390-B52E14A7-F00B-4F12-9846-8B43C4C36FFEQ37111338-5D1B600C-E182-4479-ABC2-F5B3A5D6CD30Q37125975-0EF3EED1-932F-4247-A856-EC727CDDCC8AQ37356525-9ED67FCC-ACA1-44A8-8F85-59D602C884DCQ37931236-3DA880AD-84F5-4C78-860B-002422B53636Q39717818-002DF508-51B7-4AB6-999F-7EF3CA5A32CBQ39745622-EFCF1D83-4B12-4139-9263-34ECAE7FD25FQ47117976-C1AD74DC-6A9D-4B92-AA95-015D9A20A95EQ47139871-5539031F-9EAC-4736-AA56-E99E87283BF2Q47145719-4BFBF39B-21AB-4FCE-A3E7-AE3AC4A319A2Q47783885-77C8E8E9-0F0B-4BF4-831B-6413FFCAB81DQ51893390-91B7C3F8-809B-47E9-A12D-432F40213E2EQ53546229-DD3F704B-A577-4AC7-920A-FD472430F5CAQ53644880-B11C1157-6242-4AD8-BF6A-4B7AD383D1AC
P2860
Combination therapy for the treatment of ocular neovascularization.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combination therapy for the treatment of ocular neovascularization.
@ast
Combination therapy for the treatment of ocular neovascularization.
@en
type
label
Combination therapy for the treatment of ocular neovascularization.
@ast
Combination therapy for the treatment of ocular neovascularization.
@en
prefLabel
Combination therapy for the treatment of ocular neovascularization.
@ast
Combination therapy for the treatment of ocular neovascularization.
@en
P2093
P2860
P1433
P1476
Combination therapy for the treatment of ocular neovascularization.
@en
P2093
Gregory S Robinson
John Bradley
P2860
P2888
P304
P356
10.1007/S10456-007-9069-X
P577
2007-03-13T00:00:00Z